(9ci)-3-甲基-4-(吡嗪氧基)-苯胺 | 871020-30-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (9ci)-3-甲基-4-(吡嗪氧基)-苯胺
• 英文名称: 3-methyl-4-(pyrazin-2-yloxy)aniline
• 英文别名: 3-Methyl-4-(2-pyrazinyloxy)aniline；3-methyl-4-pyrazin-2-yloxyaniline
• CAS: 871020-30-3
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: MPOWTSRUNYPBIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME TYROSINE KINASES DU RECEPTEUR ERBB
  申请人：ASTRAZENECA AB

  公开号：WO2005118572A1

  公开（公告）日：2005-12-15

  The invention concerns quinazoline derivatives of the formula (I), wherein each of R1, R2, R3, R4, R5, R6, R7, X1, Q1, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

  该发明涉及公式(I)的喹唑啉衍生物，其中R1、R2、R3、R4、R5、R6、R7、X1、Q1、m和n中的每个都具有描述中定义的任意含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤。
• [EN] hTERT MODULATORS AND METHODS OF USE<br/>[FR] MODULATEURS HTERT ET PROCÉDÉS D'UTILISATION
  申请人：UNIV ARIZONA

  公开号：WO2017095969A1

  公开（公告）日：2017-06-08

  The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the characterization of the effect of hTERT core promoter region mutants on the 5-12 G-quadruplex structure and its stability. It is believed that some of the compounds of the invention bind selectively to the G-quadruplex in the hTERT core promoter mutant, which results in reversal of the effect of mutant promoter activation.

  本发明提供hTERT调节剂及其生产和使用方法。具体来说，本发明提供了如下所述的一种化合物。该发明的一些方面基于对hTERT核心启动子区域突变体对5-12 G-四链结构及其稳定性影响的表征。据信，本发明的一些化合物选择性地结合到hTERT核心启动子突变体中的G-四链结构，从而逆转突变启动子激活的效果。
• Substituted bicyclic derivatives for the treatment of abnormal cell growth
  申请人：——

  公开号：US20020169165A1

  公开（公告）日：2002-11-14

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 5 , R 11 , m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  该发明涉及公式11的化合物，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R5、R11、m和p如本文所定义。该发明还涉及通过给予公式1的化合物治疗哺乳动物的异常细胞增长的方法，并且涉及用含有公式1的化合物的制药组合物治疗这种疾病的方法。该发明还涉及制备公式1的化合物的方法。
• Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
  申请人：Bradbury Hugh Robert

  公开号：US20070232607A1

  公开（公告）日：2007-10-04

  The invention concerns quinazoline derivatives of the formula (I), wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , Q 1 , m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

  这项发明涉及公式（I）的喹唑啉衍生物，其中R1、R2、R3、R4、R5、R6、R7、X1、Q1、m和n中的每一个都具有描述中定义的任何含义；它们的制备过程，含有它们的制药组合物以及它们在制造用作抗增殖剂的药物的过程中的使用，用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤。
• hTERT modulators and methods of use
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US10556860B2

  公开（公告）日：2020-02-11

  The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the characterization of the effect of hTERT core promoter region mutants on the 5-12 G-quadruplex structure and its stability. It is believed that some of the compounds of the invention bind selectively to the G-quadruplex in the hTERT core promoter mutant, which results in reversal of the effect of mutant promoter activation.

  本发明提供了 hTERT 调节剂及其生产和使用方法。特别是，本发明提供了如本文所述的式化合物。本发明的某些方面基于 hTERT 核心启动子区突变体对 5-12 G-四链结构及其稳定性影响的表征。据信，本发明的某些化合物可选择性地与 hTERT 核心启动子突变体中的 G-四叉体结合，从而逆转突变体启动子激活的效应。